<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1084</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕРОПРИЯТИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EVENTS</subject></subj-group></article-categories><title-group><article-title>В мире вирусных угроз, персонализированной медицины и «цифры» - о чем говорили на OpenBio-2021</article-title><trans-title-group xml:lang="en"><trans-title>In the world of viral threats, personalized medicine and big data -main topics of OpenBio-2021</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2021</year></pub-date><volume>10</volume><issue>4</issue><fpage>23</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Редакционная с.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1084">https://www.pharmjournal.ru/jour/article/view/1084</self-uri><abstract><p>Подведены итоги восьмого комплекса отраслевых мероприятий в сфере биотехнологии, биофармацевтики и вирусологии OpenBio, который прошел в наукограде Кольцово Новосибирской области 5-8 октября. В работе научной конференции и делового форума приняли участие около 6 тыс. человек.</p></abstract><trans-abstract xml:lang="en"><p>The results of the eighth set of industry events in the field of biotechnology, biopharmaceuticals and virology OpenBio, which took place in the Koltsovo science city of the Novosibirsk region on October 5-8, were summed up. About 6 thousand people took part in the scientific conference and business forum.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
